ASH 2021 | Advancements in MCL treatment
Anita Kumar
• 12 Dec 2021
Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, provides an overview of current developments in the treatment landscape of mantle cell lymphoma (MCL). Dr Kumar highlights the rise of targeted therapies such as Bruton’s tyrosine kinase (BTK) and BCL2 inhibitors, which can lead to chemotherapy-free regimens. BTK and BCL2 inhibitors can additionally be used in combination, as seen in the Phase II BOVen trial (NCT03824483), which investigated zanubrutinib and venetoclax, a BTK and BCL2 inhibitor respectively, with obinutuzumab, in patients with high-risk TP53 mutant MCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
